Glenmark Leaps Into Sub-Q Checkpoint Inhibitor Terrain With China Deal

India-China combine for subcutaneously injected PD-L1 inhibitor takes wings, with Glenmark set to take Alphamab/3D Med’s envafolimab to key emerging markets, widening access for patients.